CSF-1

DRUG4 trials

Sponsors

Orasis Pharmaceuticals Ltd.

Conditions

Presbyopia

Phase 2

A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia

CompletedNCT03885011

Orasis Pharmaceuticals Ltd.Presbyopia

Start: 2019-02-26End: 2019-07-26Updated: 2023-01-26

Phase 3

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

CompletedNCT04599972

Orasis Pharmaceuticals Ltd.Presbyopia

Start: 2020-10-26End: 2022-01-28Updated: 2024-04-04

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)

CompletedNCT04599933

Orasis Pharmaceuticals Ltd.Presbyopia

Start: 2020-10-18End: 2022-02-19Updated: 2024-04-04

An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

CompletedNCT05393895

Orasis Pharmaceuticals Ltd.Presbyopia

Start: 2022-04-22End: 2022-12-01Updated: 2025-06-11

Related Papers

Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials

Clinical Therapeutics2024-01-1114 citations